文献速递心力衰竭与心肌病

心力衰竭药物治疗中肾功能变化的全国性指导

Change in renal function associated with drug treatment in heart failure: national guidance.
PubMed 文献 · Heart · 2019-01-01

肾素-血管紧张素-醛固酮系统(RAAS)抑制剂是射血分数降低的心力衰竭(HFrEF)治疗的基石,但可能导致肾功能下降和高钾血症。英国肾脏协会与英国心力衰竭学会合作,描述了心衰、RAAS抑制剂与肾功能不全之间的相互作用,并针对HFrEF患者使用RAAS抑制剂给出了明确指导。

要点

  • 启动和滴定RAAS抑制剂时必须检测肾功能,肾功能下降30%或以上可接受。
  • 急性疾病期间,血钾>6.0 mmol/L或肌酐升高>30%时应暂时停用RAAS抑制剂。
  • 液体潴留患者需大剂量利尿剂,肾功能下降不是减少利尿剂剂量的指征。

核心结论

  • 应努力在HFrEF患者中启动、滴定并维持RAAS抑制剂治疗,无论是在急性疾病期间还是心衰恶化时。

研究设计与样本

  • 由英国肾脏协会与英国心力衰竭学会合作制定的指导文件,基于对心衰、RAAS抑制剂与肾功能不全相互作用的描述。

主要发现

  • RAAS抑制剂可能导致肾功能下降和/或高钾血症,尤其在启动和滴定期间、急性疾病期间以及心衰恶化时。
  • 临床试验中指导肾功能不全管理的证据非常少。

关键数值与推荐

  • 启动和滴定RAAS抑制剂时,必须检测肾功能;肾功能下降30%或以上可接受。
  • 急性疾病期间,没有证据表明停用RAAS抑制剂有益,但若血钾升至6.0 mmol/L以上或肌酐升高超过30%,应暂时停用RAAS抑制剂。
  • 液体潴留患者需要大剂量利尿剂,肾功能下降不是减少利尿剂剂量的指征;若患者仍充血,需要更多利尿剂。
  • 低血容量患者应停用或暂时停用利尿剂。
  • 临终阶段应考虑停用RAAS抑制剂。

临床怎么用

  • 在HFrEF患者中,应努力启动、滴定并维持RAAS抑制剂治疗,包括急性疾病期间和心衰恶化时。
  • 启动和滴定期间监测肾功能,可接受30%以内的下降。
  • 急性疾病时根据血钾和肌酐水平决定是否暂时停用RAAS抑制剂。
  • 液体潴留时不要因肾功能下降而减少利尿剂剂量。
  • 低血容量时停用或暂时停用利尿剂,临终阶段考虑停用RAAS抑制剂。

局限性

  • 临床试验中指导肾功能不全管理的证据非常少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhibitors of the renin-angiotensin-aldosterone (RAAS) system are cornerstones of the management of patients with heart failure with reduced left ventricular ejection fraction (HFrEF). However, RAAS inhibitors may cause decline in renal function and/or hyperkalaemia, particularly during initiation and titration, intercurrent illness and during worsening of heart failure. There is very little evidence from clinical trials to guide the management of renal dysfunction. The Renal Association and British Society for Heart Failure have collaborated to describe the interactions between heart failure, RAAS inhibitors and renal dysfunction and give clear guidance on the use of RAAS inhibitors in patients with HFrEF. During initiation and titration of RAAS inhibitors, testing renal function is mandatory; a decline in renal function of 30% or more can be acceptable. During intercurrent illness, there is no evidence that stopping RAAS inhibitor is beneficial, but if potassium rises above 6.0 mmol/L, or creatinine rises more than 30%, RAAS inhibitors should be temporarily withheld. In patients with fluid retention, high doses of diuretic are needed and a decline in renal function is not an indication to reduce diuretic dose: if the patient remains congested, more diuretics are required. If a patient is hypovolaemic, diuretics should be stopped or withheld temporarily. Towards end of life, consider stopping RAAS inhibitors. RAAS inhibition has no known prognostic benefit in heart failure with preserved ejection fraction. Efforts should be made to initiate, titrate and maintain patients with HFrEF on RAAS inhibitor treatment, whether during intercurrent illness or worsening heart failure.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Clark AL, Kalra PR, Petrie MC, et al. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019. PMID: 31118203. doi:10.1136/heartjnl-2018-314158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。